Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Tremelimumab
Synonyms
Therapy Description

Tremelimumab binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tremelimumab CP-675,206|Ticilimumab|CP-675206 CTLA4 Antibody 21 Immune Checkpoint Inhibitor 135 Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Recruiting 1
NCT02558894 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed USA | CAN 4
NCT02551159 Phase III Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Completed USA | CAN 21
NCT02626130 Phase I Tremelimumab Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC) Active, not recruiting USA 0
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed USA 0
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting CAN 0
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Completed USA 0
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting USA 0
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Active, not recruiting USA | CAN 4
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Active, not recruiting USA 0
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Unknown status USA 0
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated USA 0
NCT02319044 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck Completed USA | CAN 13
NCT04395079 Phase II Tremelimumab Durvalumab Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies Recruiting USA 0
NCT02262741 Phase I Tremelimumab Durvalumab A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer Completed USA | CAN 0
NCT03557918 Phase II Tremelimumab Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Recruiting USA 0
NCT02179671 Phase II Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed USA 0
NCT02141542 Phase I Tremelimumab MEDI3617 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Active, not recruiting USA 0
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Withdrawn USA 0
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed USA | CAN 4
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Active, not recruiting USA 8
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Active, not recruiting USA | CAN 24
NCT02563925 Phase I Tremelimumab Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Completed USA 0
NCT02485990 Phase Ib/II Olaparib Tremelimumab Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) Terminated USA 0
NCT02311361 Phase I Durvalumab Tremelimumab Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer Completed USA 0
NCT02301130 Phase I Mogamulizumab Durvalumab Tremelimumab Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors Completed USA 0
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC) Active, not recruiting USA | CAN 15


Additional content available in CKB BOOST